Isocitrate dehydrogenase
| Isocitrate dehydrogenase | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 | |||||||||
| Identifiers | |||||||||
| EC no. | 1.1.1.42 | ||||||||
| CAS no. | 9028-48-2 | ||||||||
| Databases | |||||||||
| IntEnz | IntEnz view | ||||||||
| BRENDA | BRENDA entry | ||||||||
| ExPASy | NiceZyme view | ||||||||
| KEGG | KEGG entry | ||||||||
| MetaCyc | metabolic pathway | ||||||||
| PRIAM | profile | ||||||||
| PDB structures | RCSB PDB PDBe PDBsum | ||||||||
| Gene Ontology | AmiGO / QuickGO | ||||||||
| |||||||||
| isocitrate dehydrogenase (NAD+) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Identifiers | |||||||||
| EC no. | 1.1.1.41 | ||||||||
| CAS no. | 9001-58-5 | ||||||||
| Databases | |||||||||
| IntEnz | IntEnz view | ||||||||
| BRENDA | BRENDA entry | ||||||||
| ExPASy | NiceZyme view | ||||||||
| KEGG | KEGG entry | ||||||||
| MetaCyc | metabolic pathway | ||||||||
| PRIAM | profile | ||||||||
| PDB structures | RCSB PDB PDBe PDBsum | ||||||||
| Gene Ontology | AmiGO / QuickGO | ||||||||
| |||||||||
| Monomeric isocitrate dehydrogenase | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 crystal structure of the monomeric isocitrate dehydrogenase in complex with isocitrate and mn | |||||||||
| Identifiers | |||||||||
| Symbol | IDH | ||||||||
| Pfam | PF03971 | ||||||||
| Pfam clan | CL0270 | ||||||||
| InterPro | IPR004436 | ||||||||
| SCOP2 | 1ofg / SCOPe / SUPFAM | ||||||||
| |||||||||
Isocitrate dehydrogenase (IDH) (EC 1.1.1.42) and (EC 1.1.1.41) is an enzyme that catalyzes the oxidative decarboxylation of isocitrate, producing alpha-ketoglutarate (α-ketoglutarate) and CO2. This is a two-step process, which involves oxidation of isocitrate (a secondary alcohol) to oxalosuccinate (a ketone), followed by the decarboxylation of the carboxyl group beta to the ketone, forming alpha-ketoglutarate. In humans, IDH exists in three isoforms: IDH3 catalyzes the third step of the citric acid cycle while converting NAD+ to NADH in the mitochondria. The isoforms IDH1 and IDH2 catalyze the same reaction outside the context of the citric acid cycle and use NADP+ as a cofactor instead of NAD+. They localize to the cytosol as well as the mitochondrion and peroxisome.[2]
Structure
[edit]
The NAD-IDH is composed of 3 subunits, is allosterically regulated, and requires an integrated Mg2+ or Mn2+ ion. The closest homologue that has a known structure is the E. coli NADP-dependent IDH, which has only 2 subunits and a 13% identity and 29% similarity based on the amino acid sequences, making it dissimilar to human IDH and not suitable for close comparison. All the known NADP-IDHs are homodimers.
Most isocitrate dehydrogenases are dimers, to be specific, homodimers (two identical monomer subunits forming one dimeric unit). In comparing C. glutamicum and E. coli,[4] monomer and dimer, respectively, both enzymes were found to "efficiently catalyze identical reactions." However, C. glutamicum was recorded as having ten times as much activity than E. coli and seven times more affinitive/specific for NADP. C. glutamicum favored NADP+ over NAD+. In terms of stability with response to temperature, both enzymes had a similar Tm or melting temperature at about 55 °C to 60 °C. However, the monomer C. glutamicum showed a more consistent stability at higher temperatures, which was expected. The dimer E. coli showed stability at a higher temperature than normal due to the interactions between the two monomeric subunits.
The structure of Mycobacterium tuberculosis (Mtb) ICDH-1 bound with NADPH and Mn(2+) bound has been solved by X-ray crystallography. It is a homodimer in which each subunit has a Rossmann fold, and a common top domain of interlocking β sheets. Mtb ICDH-1 is most structurally similar to the R132H mutant human ICDH found in CNS WHO grade 4 astrocytomas, formerly classified[5] as glioblastomas. Similar to human R132H ICDH, Mtb ICDH-1 also catalyzes the formation of α-hydroxyglutarate.[6]
Regulation
[edit]The IDH step of the citric acid cycle is often (but not always) an irreversible reaction due to its large negative change in free energy. It must therefore be carefully regulated to avoid depletion of isocitrate (and therefore an accumulation of alpha-ketoglutarate). The reaction is stimulated by the simple mechanisms of substrate availability (isocitrate, NAD+ or NADP+, Mg2+ / Mn2+ ), product inhibition by NADH (or NADPH outside the citric acid cycle) and alpha-ketoglutarate, and competitive feedback inhibition by ATP.[7] A conserved ncRNA upstream of the icd gene which codes for NADP+-dependent isocitrate dehydrogenase (IDH) has been reported in bacterial genomes, due to its characteristics this ncRNA resembles previous regulatory motifs called riboswitches, icd-II ncRNA motif has been proposed as a strong candidate riboswitch.[8]
Catalytic mechanisms
[edit]Isocitrate dehydrogenase catalyzes the chemical reactions:
- Isocitrate + NAD+ 2-oxoglutarate + CO2 + NADH + H+
- Isocitrate + NADP+ 2-oxoglutarate + CO2 + NADPH + H+[9][10][11]
The overall free energy for this reaction is -8.4 kJ/mol.[12]
Steps
[edit]Within the citric acid cycle, isocitrate, produced from the isomerization of citrate, undergoes both oxidation and decarboxylation. The enzyme isocitrate dehydrogenase (IDH) holds isocitrate within its active site using the surrounding amino acids, including arginine, tyrosine, asparagine, serine, threonine, and aspartic acid.
In the provided figure, the first box shows the overall isocitrate dehydrogenase reaction. The necessary reactants for this enzyme mechanism are isocitrate, NAD+/NADP+, and Mn2+ or Mg2+. The products of the reaction are alpha-ketoglutarate, carbon dioxide, and NADH + H+/NADPH + H+.[10] Water molecules help to deprotonate the oxygen atoms of isocitrate.
The second box in the figure illustrates step 1 of the reaction, which is the oxidation of the alpha-carbon (C2 here, also called alpha-C).[9][10] In this process,[9] the alcohol group of the alpha-carbon is deprotonated and the resulting lone pair of electrons forms a ketone group on that carbon. NAD+/NADP+ acts as an electron-accepting cofactor and collects the resulting hydride from C2. The oxidation of the alpha carbon introduces a molecular arrangement where electrons (in the next step) will flow from the nearby carboxyl group and push the electrons of the double bonded oxygen up onto the oxygen atom itself, which collects a proton from a nearby lysine.
The third box illustrates step 2, which is the decarboxylation of oxalosuccinate. In this step,[9][10] the carboxyl group oxygen is deprotonated by a nearby tyrosine, and those electrons flow down to C2. Carbon dioxide, the leaving group, detaches from the beta carbon of isocitrate (C3) and the electrons flow to the ketone oxygen attached to the alpha carbon, granting a negative charge to the associated oxygen atom and forming an alpha-beta unsaturated double bond between carbons 2 and 3.
The fourth and final box illustrates step 3, which is the saturation of the alpha-beta unsaturated double bond that formed in the previous step. The negatively charged oxygen (attached to the alpha-carbon) donates its electrons, reforming the ketone double bond and pushing another lone pair (the one that forms the double bond between the alpha and beta carbons) "off" the molecule. This lone pair, in turn, picks up a proton from the nearby tyrosine.[14] This reaction results in the formation of alpha-ketoglutarate, NADH + H+/NADPH + H+, and CO2.
Detailed mechanism
[edit]Two aspartate amino acid residues (below left) are interacting with two adjacent water molecules (w6 and w8) in the Mn2+ isocitrate porcine IDH complex to deprotonate the alcohol off the alpha-carbon atom. The oxidation of the alpha-C also takes place in this picture where NAD+ accepts a hydride resulting in oxalosuccinate. Along with the sp3 to sp2 stereochemical change around the alpha-C, there is a ketone group that is formed from the alcohol group. The formation of this ketone double bond allows for resonance to take place as electrons coming down from the leaving carboxylate group move towards the ketone.
The decarboxylation of oxalosuccinate (below center) is a key step in the formation of alpha-ketoglutarate. In this reaction, the lone pair on the adjacent Tyrosine hydroxyl abstracts the proton off the carboxyl group.[14] This carboxyl group is also referred to as the beta subunit in the isocitrate molecule. The deprotonation of the carboxyl group causes the lone pair of electrons to move down making carbon dioxide and separating from oxalosuccinate. The electrons continue to move towards the alpha carbon pushing the double bond electrons (making the ketone) up to abstract a proton off an adjacent lysine residue. An alpha-beta unsaturated double bond results between carbon 2 and three. As you can see in the picture, the green ion represents either Mg2+ or Mn2+, which is a cofactor necessary for this reaction to occur. The metal-ion forms a little complex through ionic interactions with the oxygen atoms on the fourth and fifth carbons (also known as the gamma subunit of isocitrate).
After the carbon dioxide is split from the oxalosuccinate in the decarboxylation step (below right), the enol will tautomerize to the keto from. The formation of the ketone double bond is started by the deprotonation of that oxygen off the alpha carbon (C#2) by the same lysine that protonated the oxygen in the first place.[14] The lone pair of electrons moves down kicking off the lone pairs that were making the double bond. This lone pair of electrons abstracts a proton off the Tyrosine that deprotonated the carboxyl group in the decarboxylation step. The reason that we can say that the Lys and Tyr residues will be the same from the previous step is because they are helping in holding the isocitrate molecule in the active site of the enzyme. These two residues will be able to form hydrogen bonds back and forth as long as they are close enough to the substrate.[4]
 |
 |
 |
The isocitrate dehydrogenase enzyme as stated above produces alpha-ketoglutarate, carbon dioxide, and NADH + H+/NADPH + H+. There are three changes that occurred throughout the reaction. The oxidation of Carbon 2, the decarboxylation (loss of carbon dioxide) off Carbon 3, and the formation of a ketone group with a stereochemical change from sp3 to sp2.[14]
 |
 |
 |
 |
Active site
[edit]
The Isocitrate Dehydrogenase (IDH) enzyme structure in Escherichia coli was the first IDH ortholog structure to be elucidated and understood.[14] Since then, the Escherichia coli IDH structure has been used by most researchers to make comparisons to other isocitrate dehydrogenase enzymes. There is much detailed knowledge about this bacterial enzyme, and it has been found that most isocitrate dehydrogenases are similar in structure and therefore also in function. This similarity of structure and function gives a reason to believe that the structures are conserved as well as the amino acids.[11] Therefore, the active sites amongst most prokaryotic isocitrate dehydrogenase enzymes should be conserved as well, which is observed throughout many studies done on prokaryotic enzymes. Eukaryotic isocitrate dehydrogenase enzymes on the other hand, have not been fully discovered yet. Each dimer of IDH has two active sites.[14] Each active site binds a NAD+/NADP+ molecule and a divalent metal ion (Mg2+,Mn2+). In general, each active site has a conserved sequence of amino acids for each specific binding site. In Desulfotalea psychrophila (DpIDH)[14] and porcine (PcIDH)[3] there are three substrates bound to the active site.
- Isocitrate binds within the active site to a conserved sequence of about eight amino acids through hydrogen bonds. These acids include (may vary in residue but with similar properties) tyrosine, serine, asparagine, arginine, arginine, arginine, tyrosine, and lysine. Their positions on the backbone vary but they are all within a close range (i.e. Arg131 DpIDH and Arg133 PcIDH, Tyr138 DpIDH and Tyr140 PcIDH).[14]
- The metal ion (Mg2+, Mn2+) binds to three conserved amino acids through hydrogen bonds. These amino acids include three Aspartate residues.[14]
- NAD+ and NADP+ bind within the active site within four regions with similar properties amongst IDH enzymes. These regions vary but are around [250–260], [280–290], [300–330], and [365–380]. Again regions vary but the proximity of regions are conserved.[14]
Clinical significance
[edit]
Specific mutations in the isocitrate dehydrogenase gene IDH1 have been found in several tumor types,[16] notably brain tumors including astrocytoma and oligodendroglioma.[5] Patients whose tumor had an IDH1 mutation had longer survival compared to patients whose tumor had an IDH1 wild type.[17][18] Furthermore, mutations of IDH2 and IDH1 were found in up to 20% of cytogenetically normal acute myeloid leukemia (AML).[19][20] These mutations are known to produce D-2-hydroxyglutarate from alpha-ketoglutarate.[21] D-2-hydroxyglutarate accumulates to very high concentrations which inhibits the function of enzymes that are dependent on alpha-ketoglutarate.[22] This leads to a hypermethylated state of DNA and histones, which results in different gene expression that can activate oncogenes and inactivate tumor-suppressor genes. Ultimately, this may lead to the types of cancer described above.[23] Somatic mosaic mutations of this gene have also been found associated to Ollier disease and Maffucci syndrome.[24] However, recent studies have also shown that D-2-hydroxyglutarate may be converted back into alpha-ketoglutarate either enzymatically or non-enzymatically.[25][26] Further studies are required to fully understand the roles of IDH1 mutation (and D-2-hydroxyglutarate) in cancer. Recent research highlighted cancer-causing mutations in isocitrate dehydrogenase which may cause accumulation of the metabolite D-2-hydroxyglutarate (D-2HG). Notarangelo et al. showed that such high concentrations of D-2HG could act as a direct inhibitor of lactate dehydrogenase in mouse T cells. Inhibition of this metabolic enzyme altered glucose metabolism in the T cells and inhibited their proliferation, cytokine production, and ability to kill target cells.[27]
Isozymes
[edit]The following is a list of human isocitrate dehydrogenase isozymes:
NADP+ dependent
[edit]Each NADP+-dependent isozyme functions as a homodimer:
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NAD+ dependent
[edit]The isocitrate dehydrogenase 3 isozyme is a heterotetramer that is composed of two alpha subunits, one beta subunit, and one gamma subunit:
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
See also
[edit]- Oxidoreductase
- Myelodysplastic syndrome#IDH1 and IDH2 mutations
- Oncometabolism
- Isocitrate/isopropylmalate dehydrogenase family
References
[edit]- ^ PDB: 1CW7; Cherbavaz DB, Lee ME, Stroud RM, Koshland DE (January 2000). "Active site water molecules revealed in the 2.1 A resolution structure of a site-directed mutant of isocitrate dehydrogenase". Journal of Molecular Biology. 295 (3): 377–385. doi:10.1006/jmbi.1999.3195. PMID 10623532.
- ^ Corpas FJ, Barroso JB, Sandalio LM, Palma JM, Lupiáñez JA (November 1999). "Peroxisomal NADP-Dependent Isocitrate Dehydrogenase. Characterization and Activity Regulation during Natural Senescence". Plant Physiology. 121 (3): 921–928. doi:10.1104/pp.121.3.921. PMC 59455. PMID 10557241.
- ^ a b c d e f PDB: 1LWD; Ceccarelli C, Grodsky NB, Ariyaratne N, Colman RF, Bahnson BJ (November 2002). "Crystal structure of porcine mitochondrial NADP+-dependent isocitrate dehydrogenase complexed with Mn2+ and isocitrate. Insights into the enzyme mechanism". The Journal of Biological Chemistry. 277 (45): 43454–43462. doi:10.1074/jbc.M207306200. PMID 12207025.
- ^ a b Chen R, Yang H (November 2000). "A highly specific monomeric isocitrate dehydrogenase from Corynebacterium glutamicum". Archives of Biochemistry and Biophysics. 383 (2): 238–245. doi:10.1006/abbi.2000.2082. PMID 11185559.
- ^ a b Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. (August 2021). "The 2021 WHO Classification of Tumors of the Central Nervous System: a summary". Neuro-Oncology. 23 (8): 1231–1251. doi:10.1093/neuonc/noab106. PMC 8328013. PMID 34185076.
- ^ Quartararo CE, Hazra S, Hadi T, Blanchard JS (March 2013). "Structural, kinetic and chemical mechanism of isocitrate dehydrogenase-1 from Mycobacterium tuberculosis". Biochemistry. 52 (10): 1765–1775. doi:10.1021/bi400037w. PMC 3706558. PMID 23409873.
- ^ Maeting I, Schmidt G, Sahm H, Stahmann KP (2000). "Role of a peroxisomal NADP-specific isocitrate dehydrogenase in the metabolism of the riboflavin overproducer Ashbya gossypii". Journal of Molecular Catalysis B: Enzymatic. 10 (1–3): 335–343. doi:10.1016/S1381-1177(00)00135-1.
- ^ Brewer KI, Greenlee EB, Higgs G, Yu D, Mirihana Arachchilage G, Chen X, et al. (December 2021). "Comprehensive discovery of novel structured noncoding RNAs in 26 bacterial genomes". RNA Biology. 18 (12): 2417–2432. doi:10.1080/15476286.2021.1917891. PMC 8632094. PMID 33970790. S2CID 234361097.
- ^ a b c d Begley TP, McMurry J (2005). The Organic Chemistry of Biological Pathways. Roberts and Co. Publishers. pp. 189–190. ISBN 0-9747077-1-6.
- ^ a b c d Cox M, Nelson DR, Lehninger AL (2005). Lehninger Principles of Biochemistry. San Francisco: W.H. Freeman. pp. 609–611. ISBN 0-7167-4339-6.
- ^ a b Yasutake Y, Watanabe S, Yao M, Takada Y, Fukunaga N, Tanaka I (September 2003). "Crystal structure of the monomeric isocitrate dehydrogenase in the presence of NADP+: insight into the cofactor recognition, catalysis, and evolution". The Journal of Biological Chemistry. 278 (38): 36897–36904. doi:10.1074/jbc.M304091200. PMID 12855708.
- ^ Garrett R, Grisham CM (2012). Biochemistry. Cengage Learning. p. 621. ISBN 978-1-133-10629-6.
- ^ Aoshima M, Igarashi Y (March 2008). "Nondecarboxylating and decarboxylating isocitrate dehydrogenases: oxalosuccinate reductase as an ancestral form of isocitrate dehydrogenase". Journal of Bacteriology. 190 (6): 2050–2055. doi:10.1128/JB.01799-07. PMC 2258884. PMID 18203822.
- ^ a b c d e f g h i j k l m Fedøy AE, Yang N, Martinez A, Leiros HK, Steen IH (September 2007). "Structural and functional properties of isocitrate dehydrogenase from the psychrophilic bacterium Desulfotalea psychrophila reveal a cold-active enzyme with an unusual high thermal stability". Journal of Molecular Biology. 372 (1): 130–149. doi:10.1016/j.jmb.2007.06.040. PMID 17632124.
- ^ Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A (November 2009). "Monoclonal antibody specific for IDH1 R132H mutation". Acta Neuropathologica. 118 (5): 599–601. doi:10.1007/s00401-009-0595-z. PMID 19798509. S2CID 36093146.
- ^ Zarei M, Hue JJ, Hajihassani O, Graor HJ, Katayama ES, Loftus AW, et al. (February 2022). "Clinical development of IDH1 inhibitors for cancer therapy". Cancer Treatment Reviews. 103: 102334. doi:10.1016/j.ctrv.2021.102334. PMID 34974243. S2CID 245547597.
- ^ Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, et al. (December 2010). "Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas" (PDF). Acta Neuropathologica. 120 (6): 707–718. doi:10.1007/s00401-010-0781-z. PMID 21088844. S2CID 7323032.
- ^ Molenaar RJ, Verbaan D, Lamba S, Zanon C, Jeuken JW, Boots-Sprenger SH, et al. (September 2014). "The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone". Neuro-Oncology. 16 (9): 1263–1273. doi:10.1093/neuonc/nou005. PMC 4136888. PMID 24510240.
- ^ Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, et al. (March 2010). "The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate". Cancer Cell. 17 (3): 225–234. doi:10.1016/j.ccr.2010.01.020. PMC 2849316. PMID 20171147.
- ^ Wang Y, Xiao M, Chen X, Chen L, Xu Y, Lv L, et al. (February 2015). "WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation". Molecular Cell. 57 (4): 662–673. doi:10.1016/j.molcel.2014.12.023. PMC 4336627. PMID 25601757.
- ^ Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. (June 2010). "Cancer-associated IDH1 mutations produce 2-hydroxyglutarate". Nature. 465 (7300): 966. Bibcode:2010Natur.465..966D. doi:10.1038/nature09132. PMC 3766976. PMID 20559394.
- ^ Chowdhury R, Yeoh KK, Tian YM, Hillringhaus L, Bagg EA, Rose NR, et al. (May 2011). "The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases". EMBO Reports. 12 (5): 463–469. doi:10.1038/embor.2011.43. PMC 3090014. PMID 21460794.
- ^ Molenaar RJ, Radivoyevitch T, Maciejewski JP, van Noorden CJ, Bleeker FE (December 2014). "The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation". Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1846 (2): 326–341. doi:10.1016/j.bbcan.2014.05.004. PMID 24880135.
- ^ Amary MF, Damato S, Halai D, Eskandarpour M, Berisha F, Bonar F, et al. (November 2011). "Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2". Nature Genetics. 43 (12): 1262–1265. doi:10.1038/ng.994. PMID 22057236. S2CID 5592593.
- ^ Tarhonskaya H, Rydzik AM, Leung IK, Loik ND, Chan MC, Kawamura A, et al. (March 2014). "Non-enzymatic chemistry enables 2-hydroxyglutarate-mediated activation of 2-oxoglutarate oxygenases". Nature Communications. 5: 3423. Bibcode:2014NatCo...5.3423T. doi:10.1038/ncomms4423. PMC 3959194. PMID 24594748.
- ^ Koivunen P, Lee S, Duncan CG, Lopez G, Lu G, Ramkissoon S, et al. (February 2012). "Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation". Nature. 483 (7390): 484–488. Bibcode:2012Natur.483..484K. doi:10.1038/nature10898. PMC 3656605. PMID 22343896.
- ^ Notarangelo G, Spinelli JB, Perez EM, Baker GJ, Kurmi K, Elia I, et al. (September 2022). "Oncometabolite d-2HG alters T cell metabolism to impair CD8+ T cell function". Science. 377 (6614): 1519–1529. Bibcode:2022Sci...377.1519N. doi:10.1126/science.abj5104. PMC 9629749. PMID 36173860. S2CID 252623286.
External links
[edit]- Isocitrate dehydrogenase: RCSB PDB Molecule of the Month Archived 2013-12-24 at the Wayback Machine
- Overview of all the structural information available in the PDB for UniProt: O75874 (Isocitrate dehydrogenase [NADP] cytoplasmic) at the PDBe-KB.
- Overview of all the structural information available in the PDB for UniProt: P48735 (Isocitrate dehydrogenase [NADP], mitochondrial) at the PDBe-KB.
- Overview of all the structural information available in the PDB for UniProt: P50213 (Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial) at the PDBe-KB.
- Overview of all the structural information available in the PDB for UniProt: O43837 (Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial) at the PDBe-KB.
- Overview of all the structural information available in the PDB for UniProt: P51553 (Isocitrate dehydrogenase [NAD] subunit gamma, mitochondrial) at the PDBe-KB.
